You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Genzyme wins approval of multiple sclerosis drug

Federal regulators Wednesday night gave Genzyme Corp. the go-ahead to sell a new pill to treat multiple sclerosis in the United States.

The positive ruling for the Cambridge biotechnology company’s therapy, called Aubagio, marks the Food and Drug Administration’s first approval of a Genzyme drug since French pharmaceutical giant Sanofi SA bought Genzyme for $20.1 billion in 2010.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week